`ECEIVED
`
`IN THE UNITED ST A TES DISTRICT COURT
`FOR THE DISTRICT OF NEW JERSEY
`
`I
`I
`' i
`
`FEB 2 3 2017
`
`. M
`AT 8:30
`WILLIAM T. WALSH .~
`CLERK
`
`I
`
`HORIZON PHARMA, INC., and POZEN,
`INC.,
`
`Civil Action No. 3: 15-cv-03. 27-MLC-DEA
`
`Plaintiffs,
`
`v.
`
`MYLAN PHARMACEUTICALS INC.,
`MYLAN LABORATORIES LIMITED, and
`MYLAN INC ..
`
`Defendants.
`
`STIPULATION AND i!:R:dl'm't'If ORDER
`TO DISMISS CERTAIN
`COUNTERCLAIMS
`
`WHEREAS Defendants Mylan Pharmaceuticals Inc., Mylan Labora ories Ltd., and Mylan
`
`Inc. (collectively, ''Mylan") pleaded counterclaims of noninfringement and i validity of U.S. Patent
`
`No. 9,220,698 ("'the '698 patent") in the above-referenced action Civil A tion No. 15-cv-03327
`
`(consolidated as Civil Action No. 15-cv-03322) ("Case II");
`
`WHEREAS Plaintiffs Horizon Pharma Inc. ("Horizon") and
`
`ozen, Inc. ("Pozen")
`
`(collectively, "Plaintiffs") alleged infringement of the '698 patent by Defen ants in a later action,
`
`Civil Action No. I 6-cv-0492 I ("Case III") in this Court;
`
`WHEREAS Plaintiffs and Mylan exchanged contentions for the '69 patent pursuant to L.
`
`Pat. R. 3.3 and 3.6 and the Scheduling Order (D.E. 42 in Civil Action No. l 5.~cv-003322) in Case II
`
`and L. Pat. R. 3.3 and 3.6 and the Scheduling Order (D.E. 40) in Case III;
`
`WHEREAS Plaintiffs also alleged infringement of U.S. Patent No. 9,393,208 ("the '208
`
`patent") by Defendants in Case III;
`
`WHEREAS the '208 patent is a continuation of the '698 patent;
`
`WHEREAS Plaintiffs and Defendants seek to promote judicial efficie ·,cy;
`
`2
`
`MYLAN PHARMS. INC. EXHIBIT 1047 PAGE 1
`
`
`
`Case 3:15-cv-03327-MLC-DEA Document 40 Filed 02/23/17 Page 2 of 3 PageID: 710
`
`THEREFORE, IT IS HEREBY STIPULATED, CONSENTED, AN ·;AGREED TO by and
`
`between the parties hereto as follows:
`
`1.
`
`The parties stipulate to dismiss Mylan's sixth and twelfth cou terclaitns (declaratory
`
`judgment of noninfringement and invalidity of U.S. Patent No. 9,220,69 , respectively) in the
`
`above-referenced action, Case II, without prejudice. This stipulation of dismissal does not apply to
`
`the claims or counterclaims related to the '698 and '208 patents in Case III.
`
`So stipulated,
`
`Dated: February 17, 2017
`
`Respectfully Submitted,
`
`s/ Gregory D. Miller
`By:
`Gregory D. Miller
`(GMiller@rivkin.com)
`Nancy A. Del Pizzo
`(Nancy.Delpizzo@rivkin.com)
`Gene Y. Kang
`(Gene.Kang@rivkin.com)
`RIVKIN RADLER LLP
`21 Main Street, Suite 158 ·
`Hackensack, NJ 07601
`(201) 287-2460 (telephone)
`(202) 489-0495 (facsimile)
`
`Shannon M. Bloodworth
`(SBloodworth@perkinscoie.com)
`Brandon M. White
`(BMWhite@perkinscoie.com)
`Robert Swanson
`(RSwanson@perkinscoie.com)
`PERKINS Corn LLP
`700 Thirteenth StreetN.W., Suite 600
`Washington, D.C. 20005-3960
`(202) 654-6200 (telephone)
`(202) 654-9134 (facsimile)
`
`Autumn N. Nero
`(ANero@perkinscoie.com)
`Melody K. Glazer
`(MGlazer@perkinscoie.com)
`Emily Greb
`
`1
`
`s/ John E. Flaher
`By:
`John E. Flaherty
`Jonathan M. H. Short
`McCARTER & ENGLIS
`Fout Gateway Center
`100 Mulberry Street
`Newark, New Jersey 0710
`(973) 622-4444
`
`, LLP
`
`Of Counsel for Plaintiffs A : traZeneca AB,
`Inc.
`AstraZeneca LP, and KB!-
`
`Stephen M. Hash
`Jeff Gritton
`BAKER BOTTS, LLP
`98 Jacinto Boulevard, Suit 1500
`Austin, TX 98701-4078
`(512) 322-2587 (telephone
`(512) 322-3687 (facsimile)
`
`Of Counsel for Plaintiff Po en Inc.
`
`Ricardo Rodriguez
`COOLEYLLP
`31 7 5 Hanover Street
`Palo Alto, CA 94304-1130
`( 650) 843-5000
`
`Of Counsel for Plaintiff Ho izon Pharma,
`Inc.
`
`3
`
`MYLAN PHARMS. INC. EXHIBIT 1047 PAGE 2
`
`
`
`Case 3:15-cv-03327-MLC-DEA Document 40 Filed 02/23/17 Page 3 of 3 PageID: 711
`
`Ii
`
`:11
`'I
`·.1
`
`1
`
`(EGreb@perkinscoie.com)
`PERKINS COIE LLP
`One East Main Street, Suite 20 I
`Madison, Wisconsin 53703-5118
`(608) 663-7460 (telephone)
`(608) 663-7499 (facsimile)
`
`Bryan D. Beel
`(BBeel@perkinscoie.com)
`PERKINS COIE LLP
`1120 NW Couch Street, 10th Floor
`Portland, OR 97209
`(503) 727-2000 (telephone)
`(503) 346-2116 (facsimile)
`
`Attorneys.for Defendants/Counterclaim
`Pfoint?ffs Mylan Pharmaceuticals Inc.,
`Mylan laboratories ltd., and
`Mylan Inc.
`
`IT IS SO ORDERED.
`
`Dated: efl/002.-/11
`
`I
`
`I
`
`4
`
`MYLAN PHARMS. INC. EXHIBIT 1047 PAGE 3
`
`